Compare $BCRX vs $NRIX | Chartloom

Compare

$BCRX vs $NRIX

BioCryst Pharmaceuticals Inc · Nurix Therapeutics Inc

BCRX

BioCryst Pharmaceuticals Inc

NRIX

Nurix Therapeutics Inc

Compare $BCRX vs $NRIX

Comparing BioCryst Pharmaceuticals Inc and Nurix Therapeutics Inc

BCRXBioCryst Pharmaceuticals Inc

NRIXNurix Therapeutics Inc

BCRXBioCryst Pharmaceuticals Inc

Market cap

$2.17B

P/E (TTM)

—

Forward P/E (NTM)

16.67x

Forward P/S (NTM)

3.13x

Rev growth (TTM)

68.7%

YTD performance

14.0%

52W performance

17.4%

FCF yield

17.9%

NRIXNurix Therapeutics Inc

Market cap

$2.32B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

24.84x

Rev growth (TTM)

-58.4%

YTD performance

23.8%

52W performance

123.9%

FCF yield

-13.1%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

BCRX

NRIX

Detailed metrics comparison

BCRX

BioCryst Pharmaceuticals Inc

NRIX

Nurix Therapeutics Inc

Market Cap

BCRX$2.17B

NRIX$2.32B

Enterprise Value

BCRX$2.84B

NRIX$2.25B

Price

BCRX$8.55

NRIX$22.35

P/E Ratio

BCRXN/A

NRIXN/A

P/S Ratio

BCRX2.31x

NRIX63.09x

EV/Sales

BCRX3.02x

NRIX61.25x

EV/EBITDA

BCRX6.85x

NRIX0.00x

P/B Ratio

BCRX62.13x

NRIX5.93x

P/FCF Ratio

BCRX5.59x

NRIXN/A

EV/FCF

BCRX7.32x

NRIX-7.39x

PEG Ratio

BCRXN/A

NRIXN/A

Forward P/E (NTM)

BCRX16.67x

NRIXN/A

Forward P/S (NTM)

BCRX3.13x

NRIX24.84x

Revenue (TTM)

BCRX$941M

NRIX$37M

Revenue Growth (YoY)

BCRX68.7%

NRIX-58.4%

Forward Rev Growth

BCRX3.9%

NRIX66.6%

Gross Margin (TTM)

BCRX97.8%

NRIX0.0%

Operating Margin (TTM)

BCRX0.0%

NRIX0.0%

EBITDA Margin (TTM)

BCRX41.1%

NRIX-959.0%

Net Margin (TTM)

BCRX-40.9%

NRIX-928.4%

FCF Margin (TTM)

BCRX41.3%

NRIX-828.3%

Net Income (TTM)

BCRX$-385M

NRIX$-341M

FCF (TTM)

BCRX$388M

NRIX$-305M

EPS (TTM)

BCRX-$1.45

NRIX-$3.07

ROE (TTM)

BCRX-32882.0%

NRIX-7609.0%

ROA (TTM)

BCRX-7758.0%

NRIX-5732.0%

ROIC (TTM)

BCRX-10666.0%

NRIX-7609.0%

Cash

BCRX$155M

NRIX$68M

Debt

BCRX$824M

NRIX$0

Net Cash/Debt

BCRX$-669M

NRIX$68M

Current Ratio (TTM)

BCRX2.32x

NRIX6.34x

Quick Ratio (TTM)

BCRX2.22x

NRIX6.16x

Debt/Equity (TTM)

BCRX2.26x

NRIX0.00x

Debt/Assets (TTM)

BCRX0.0%

NRIX0.0%

Interest Coverage (TTM)

BCRXN/A

NRIXN/A

Net Debt/EBITDA (TTM)

BCRX0.00x

NRIX0.00x

Beta

BCRX0.54

NRIX1.78

52W Performance

BCRX17.4%

NRIX123.9%

YTD Performance

BCRX14.0%

NRIX23.8%

% from 52W High

BCRX-23.8%

NRIX-20.8%

% from 52W Low

BCRX42.5%

NRIX148.3%

Asset Turnover (TTM)

BCRX1.90x

NRIX0.06x

FCF Yield (TTM)

BCRX17.9%

NRIX-13.1%

Earnings Yield (TTM)

BCRX-17.7%

NRIX-14.7%

Dividend Yield (TTM)

BCRXN/A

NRIXN/A

Rule of 40

BCRX110.0

NRIX-886.7

EV/GP/RG

BCRX0.74

NRIXN/A

Ticker research

View BCRX research View NRIX research

Metric	BCRX BioCryst Pharmaceuticals Inc	NRIX Nurix Therapeutics Inc
Market & Valuation
Market Cap	$2.17B	$2.32B
Enterprise Value	$2.84B	$2.25B
Price	$8.55	$22.35
P/E Ratio	N/A	N/A
P/S Ratio	2.31x	63.09x
EV/Sales	3.02x	61.25x
EV/EBITDA	6.85x	0.00x
P/B Ratio	62.13x	5.93x
P/FCF Ratio	5.59x	N/A
EV/FCF	7.32x	-7.39x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	16.67x	N/A
Forward P/S (NTM)	3.13x	24.84x
Revenue & Growth
Revenue (TTM)	$941M	$37M
Revenue Growth (YoY)	68.7%	-58.4%
Forward Rev Growth	3.9%	66.6%
Profitability
Gross Margin (TTM)	97.8%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	41.1%	-959.0%
Net Margin (TTM)	-40.9%	-928.4%
FCF Margin (TTM)	41.3%	-828.3%
Net Income (TTM)	$-385M	$-341M
FCF (TTM)	$388M	$-305M
EPS (TTM)	-$1.45	-$3.07
ROE (TTM)	-32882.0%	-7609.0%
ROA (TTM)	-7758.0%	-5732.0%
ROIC (TTM)	-10666.0%	-7609.0%
Financial Health
Cash	$155M	$68M
Debt	$824M	$0
Net Cash/Debt	$-669M	$68M
Current Ratio (TTM)	2.32x	6.34x
Quick Ratio (TTM)	2.22x	6.16x
Debt/Equity (TTM)	2.26x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.54	1.78
52W Performance	17.4%	123.9%
YTD Performance	14.0%	23.8%
% from 52W High	-23.8%	-20.8%
% from 52W Low	42.5%	148.3%
Efficiency & Yields
Asset Turnover (TTM)	1.90x	0.06x
FCF Yield (TTM)	17.9%	-13.1%
Earnings Yield (TTM)	-17.7%	-14.7%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	110.0	-886.7
EV/GP/RG	0.74	N/A
Ticker research	View BCRX research	View NRIX research

Valuation

P/S Ratio

BCRX

2.31x

NRIX

63.09x

EV/FCF

NRIX

-7.39x

BCRX

7.32x

Growth & revenue

Revenue Growth TTM

BCRX

68.7%

NRIX

-58.4%

Forward Revenue Growth

NRIX

66.6%

BCRX

3.9%

Profitability & performance

Gross Margin

BCRX

97.8%

NRIX

0.0%

ROE

NRIX

-7609.0%

BCRX

-32882.0%

FCF Yield %

BCRX

17.9%

NRIX

-13.1%

52-Week Performance

NRIX

123.9%

BCRX

17.4%

Detailed metrics comparison

BCRX

BioCryst Pharmaceuticals Inc

NRIX

Nurix Therapeutics Inc

Market Cap

BCRX$2.17B

NRIX$2.32B

Enterprise Value

BCRX$2.84B

NRIX$2.25B

Price

BCRX$8.55

NRIX$22.35

P/E Ratio

BCRXN/A

NRIXN/A

P/S Ratio

BCRX2.31x

NRIX63.09x

EV/Sales

BCRX3.02x

NRIX61.25x

EV/EBITDA

BCRX6.85x

NRIX0.00x

P/B Ratio

BCRX62.13x

NRIX5.93x

P/FCF Ratio

BCRX5.59x

NRIXN/A

EV/FCF

BCRX7.32x

NRIX-7.39x

PEG Ratio

BCRXN/A

NRIXN/A

Forward P/E (NTM)

BCRX16.67x

NRIXN/A

Forward P/S (NTM)

BCRX3.13x

NRIX24.84x

Revenue (TTM)

BCRX$941M

NRIX$37M

Revenue Growth (YoY)

BCRX68.7%

NRIX-58.4%

Forward Rev Growth

BCRX3.9%

NRIX66.6%

Gross Margin (TTM)

BCRX97.8%

NRIX0.0%

Operating Margin (TTM)

BCRX0.0%

NRIX0.0%

EBITDA Margin (TTM)

BCRX41.1%

NRIX-959.0%

Net Margin (TTM)

BCRX-40.9%

NRIX-928.4%

FCF Margin (TTM)

BCRX41.3%

NRIX-828.3%

Net Income (TTM)

BCRX$-385M

NRIX$-341M

FCF (TTM)

BCRX$388M

NRIX$-305M

EPS (TTM)

BCRX-$1.45

NRIX-$3.07

ROE (TTM)

BCRX-32882.0%

NRIX-7609.0%

ROA (TTM)

BCRX-7758.0%

NRIX-5732.0%

ROIC (TTM)

BCRX-10666.0%

NRIX-7609.0%

Cash

BCRX$155M

NRIX$68M

Debt

BCRX$824M

NRIX$0

Net Cash/Debt

BCRX$-669M

NRIX$68M

Current Ratio (TTM)

BCRX2.32x

NRIX6.34x

Quick Ratio (TTM)

BCRX2.22x

NRIX6.16x

Debt/Equity (TTM)

BCRX2.26x

NRIX0.00x

Debt/Assets (TTM)

BCRX0.0%

NRIX0.0%

Interest Coverage (TTM)

BCRXN/A

NRIXN/A

Net Debt/EBITDA (TTM)

BCRX0.00x

NRIX0.00x

Beta

BCRX0.54

NRIX1.78

52W Performance

BCRX17.4%

NRIX123.9%

YTD Performance

BCRX14.0%

NRIX23.8%

% from 52W High

BCRX-23.8%

NRIX-20.8%

% from 52W Low

BCRX42.5%

NRIX148.3%

Asset Turnover (TTM)

BCRX1.90x

NRIX0.06x

FCF Yield (TTM)

BCRX17.9%

NRIX-13.1%

Earnings Yield (TTM)

BCRX-17.7%

NRIX-14.7%

Dividend Yield (TTM)

BCRXN/A

NRIXN/A

Rule of 40

BCRX110.0

NRIX-886.7

EV/GP/RG

BCRX0.74

NRIXN/A

Ticker research

View BCRX research View NRIX research

Metric	BCRX BioCryst Pharmaceuticals Inc	NRIX Nurix Therapeutics Inc
Market & Valuation
Market Cap	$2.17B	$2.32B
Enterprise Value	$2.84B	$2.25B
Price	$8.55	$22.35
P/E Ratio	N/A	N/A
P/S Ratio	2.31x	63.09x
EV/Sales	3.02x	61.25x
EV/EBITDA	6.85x	0.00x
P/B Ratio	62.13x	5.93x
P/FCF Ratio	5.59x	N/A
EV/FCF	7.32x	-7.39x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	16.67x	N/A
Forward P/S (NTM)	3.13x	24.84x
Revenue & Growth
Revenue (TTM)	$941M	$37M
Revenue Growth (YoY)	68.7%	-58.4%
Forward Rev Growth	3.9%	66.6%
Profitability
Gross Margin (TTM)	97.8%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	41.1%	-959.0%
Net Margin (TTM)	-40.9%	-928.4%
FCF Margin (TTM)	41.3%	-828.3%
Net Income (TTM)	$-385M	$-341M
FCF (TTM)	$388M	$-305M
EPS (TTM)	-$1.45	-$3.07
ROE (TTM)	-32882.0%	-7609.0%
ROA (TTM)	-7758.0%	-5732.0%
ROIC (TTM)	-10666.0%	-7609.0%
Financial Health
Cash	$155M	$68M
Debt	$824M	$0
Net Cash/Debt	$-669M	$68M
Current Ratio (TTM)	2.32x	6.34x
Quick Ratio (TTM)	2.22x	6.16x
Debt/Equity (TTM)	2.26x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.54	1.78
52W Performance	17.4%	123.9%
YTD Performance	14.0%	23.8%
% from 52W High	-23.8%	-20.8%
% from 52W Low	42.5%	148.3%
Efficiency & Yields
Asset Turnover (TTM)	1.90x	0.06x
FCF Yield (TTM)	17.9%	-13.1%
Earnings Yield (TTM)	-17.7%	-14.7%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	110.0	-886.7
EV/GP/RG	0.74	N/A
Ticker research	View BCRX research	View NRIX research